Nabriva Therapeutics AG (NBRV) Major Shareholder Hbm Healthcare Investments (Ca Sells 44,231 Shares

Nabriva Therapeutics AG (NASDAQ:NBRV) major shareholder Hbm Healthcare Investments (Ca sold 44,231 shares of the company’s stock in a transaction dated Thursday, July 20th. The stock was sold at an average price of $10.50, for a total transaction of $464,425.50. Following the sale, the insider now directly owns 2,421,367 shares in the company, valued at $25,424,353.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Hbm Healthcare Investments (Ca also recently made the following trade(s):

  • On Tuesday, July 18th, Hbm Healthcare Investments (Ca sold 69,854 shares of Nabriva Therapeutics AG stock. The shares were sold at an average price of $10.51, for a total transaction of $734,165.54.
  • On Thursday, July 13th, Hbm Healthcare Investments (Ca sold 57,175 shares of Nabriva Therapeutics AG stock. The shares were sold at an average price of $10.53, for a total transaction of $602,052.75.
  • On Friday, July 7th, Hbm Healthcare Investments (Ca sold 2,695 shares of Nabriva Therapeutics AG stock. The shares were sold at an average price of $10.52, for a total transaction of $28,351.40.
  • On Friday, June 30th, Hbm Healthcare Investments (Ca sold 1,775 shares of Nabriva Therapeutics AG stock. The shares were sold at an average price of $10.94, for a total transaction of $19,418.50.
  • On Monday, July 3rd, Hbm Healthcare Investments (Ca sold 13,127 shares of Nabriva Therapeutics AG stock. The shares were sold at an average price of $10.94, for a total transaction of $143,609.38.
  • On Thursday, June 29th, Hbm Healthcare Investments (Ca sold 8,558 shares of Nabriva Therapeutics AG stock. The shares were sold at an average price of $10.96, for a total transaction of $93,795.68.
  • On Friday, April 28th, Hbm Healthcare Investments (Ca sold 15,939 shares of Nabriva Therapeutics AG stock. The shares were sold at an average price of $11.02, for a total transaction of $175,647.78.

Shares of Nabriva Therapeutics AG (NBRV) remained flat at $10.49 during midday trading on Friday. The company’s stock had a trading volume of 50 shares. Nabriva Therapeutics AG has a 52 week low of $3.52 and a 52 week high of $12.75. The firm’s market cap is $28.54 million. The firm has a 50 day moving average price of $10.10 and a 200 day moving average price of $10.07.

TRADEMARK VIOLATION WARNING: “Nabriva Therapeutics AG (NBRV) Major Shareholder Hbm Healthcare Investments (Ca Sells 44,231 Shares” was reported by BNB Daily and is the property of of BNB Daily. If you are accessing this story on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this story can be read at https://www.baseball-news-blog.com/2017/07/23/nabriva-therapeutics-ag-nbrv-major-shareholder-hbm-healthcare-investments-ca-sells-44231-shares.html.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in NBRV. Renaissance Technologies LLC bought a new position in Nabriva Therapeutics AG during the fourth quarter worth about $103,000. Almanack Investment Partners LLC. acquired a new position in Nabriva Therapeutics AG during the first quarter valued at $1,870,000. Nationwide Fund Advisors acquired a new position in Nabriva Therapeutics AG during the first quarter valued at $2,074,000. Finally, Wellington Management Group LLP increased its position in Nabriva Therapeutics AG by 9.9% in the first quarter. Wellington Management Group LLP now owns 2,154,261 shares of the biotechnology company’s stock valued at $25,830,000 after buying an additional 193,951 shares during the last quarter. Institutional investors own 56.73% of the company’s stock.

NBRV has been the topic of a number of recent research reports. Needham & Company LLC reaffirmed a “buy” rating and issued a $15.00 price objective on shares of Nabriva Therapeutics AG in a research note on Monday, March 27th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $16.00 price objective on shares of Nabriva Therapeutics AG in a research note on Tuesday, April 11th. HC Wainwright reaffirmed a “buy” rating on shares of Nabriva Therapeutics AG in a research note on Friday, May 12th. Wedbush reaffirmed an “outperform” rating and issued a $13.00 price objective on shares of Nabriva Therapeutics AG in a research note on Monday, May 15th. Finally, Zacks Investment Research upgraded shares of Nabriva Therapeutics AG from a “hold” rating to a “buy” rating and set a $11.00 target price on the stock in a report on Saturday, May 27th. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Nabriva Therapeutics AG currently has a consensus rating of “Buy” and an average price target of $15.43.

Nabriva Therapeutics AG Company Profile

Nabriva Therapeutics AG is an Austria-based clinical-stage biopharmaceutical company engaged in the research and development of antibiotics to treat infections. Its lead product candidate, lefamulin, is a pleuromutilin antibiotic for systemic administration in humans. The Company develops both intravenous (IV) and oral formulations of lefamulin for the treatment of community-acquired bacterial pneumonia (CABP).

Insider Buying and Selling by Quarter for Nabriva Therapeutics AG (NASDAQ:NBRV)

Receive News & Ratings for Nabriva Therapeutics AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics AG and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply